SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Spark Therapeutics, Inc. to Roche is Fair to Shareholders

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- To: All Persons or Entities who purchased Spark Therapeutics, Inc. (“Spark” or the “Company”) (NASDAQGS: ONCE) stock prior to February 25, 2019.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Spark to Roche (OTCQX: RHHBY) for US$114.50 per share. To learn more about the action and your rights, go to:

https://www.zlk.com/mna/spark-therapeutics-inc

 or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The Spark merger investigation concerns whether the Board of Spark breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Roche is underpaying for Spark shares, thus unlawfully harming Spark shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.